New CGM system combined with Basal-IQ™ technology
predicts and prevents lows with 'No Fingersticks*' for people
living with diabetes
EDINBURGH,
Scotland , Dec. 23,
2019 /PRNewswire/ -- DexCom, Inc. (NASDAQ: DXCM), a
leader in continuous glucose monitoring (CGM), has partnered with
Tandem Diabetes Care in the UK, Sweden, Italy
and Spain to distribute the Dexcom
G6 CGM System integrated with the Tandem Diabetes Care t:slim X2
insulin pump for people with diabetes.
Tandem's t:slim X2 insulin pump with Basal-IQ™ technology uses
Dexcom G6 CGM readings to predict glucose levels 30 minutes ahead
and suspend insulin delivery when glucose is predicted to go low.
Insulin delivery resumes as soon as sensor glucose values begin to
rise. Use of the integrated system reduced the time spent below 3.9
mmol/L (70 mg/dL) by 31 percent compared to use of a CGM-integrated
pump without automated insulin suspension1.
"Combining the Dexcom G6 with Tandem's t:slim X2 insulin pump
will meaningfully improve diabetes management. Not only does the
system eliminate the need for fingersticks*, but it also helps
patients reduce the frequency and duration of low-glucose events,"
said Erik Bjorkman, Dexcom's General
Manager for EMEA.
Furthermore, with the Dexcom G6 app, users can share their
glucose information with up to five people 2.
Whether you are a parent of a child with diabetes or an adult, the
Dexcom G6 lets you seamlessly keep track of glucose levels and
enables the user's care team to remotely monitor their loved ones
for extra peace of mind.
"The t:slim X2 insulin pump with Basal-IQ technology, combined
with the Dexcom G6, presents a meaningful advancement in the
automated insulin delivery category, offering people with diabetes
a simple-to-use system that predicts and helps prevent lows with
zero fingersticks," said Brian
Hansen, Executive Vice President and Chief Commercial
Officer for Tandem Diabetes Care.
The groundbreaking Dexcom G6 encompasses features that empower
users to take control of their diabetes:
- Elimination of fingersticks* for calibration or diabetes
treatment decisions.
· Customisable alarms and alerts to warn users and their
designated followers of dangerous glucose levels, even while they
are asleep – a particularly useful feature for children and those
with impaired hypoglycaemia awareness.
- An extended 10-day sensor.
- An auto-applicator designed to make sensor insertion very
simple and painless with the touch of a button.
- Continuous glucose readings sent automatically using Bluetooth
technology to any compatible smart device3, or to an
optional Dexcom receiver, at five-minute intervals.
- New sensor membrane that enables
Paracetamol4 use without any effect on glucose
readings.
The CE Marking confirms that the G6 system meets the Essential
Requirements of the Medical Device Directive MDD 93/42/EEC as
amended by 2007/47/EC. The powerful and ground-breaking new system
is also the first CGM system to receive the US Food and Drug
Administration's (FDA) De Novo classification. With this new
classification, the Dexcom G6 CGM system is indicated for use as
both a stand-alone CGM and for integration into automated insulin
dosing (AID) systems. For more information on Dexcom G6,
visit www.dexcom.com/global.
About Dexcom G6
The Dexcom G6 is a stand-alone CGM system for MDI users, which
represent the vast majority of the type 1 population, and can also
be used by anyone on insulin pump therapy. With the G6, the sensor
is worn separately from an insulin pump and is inserted under the
skin to measure the level of glucose in the interstitial fluid
(fluid in the tissue). The sensor is disposable and should be
changed every 10 days.
About DexCom, Inc.
Founded in 1999, DexCom, Inc. has corporate offices in
San Diego, California, EMEA
headquarters in Edinburgh,
Scotland and users in 39 countries around the world. At
Dexcom, we are transforming diabetes care and management by
providing superior continuous glucose monitoring (CGM) technology
to help people with diabetes and healthcare professionals better
manage diabetes. Since our inception, we have focused on better
outcomes for people with diabetes, caregivers, and clinicians by
delivering solutions that are best in class-while empowering our
community to take control of diabetes. For more information on
Dexcom CGM, visit www.dexcom.com/global.
About the Tandem Diabetes Care t:slim X2 Insulin Pump with
Basal-IQ Technology
The simple-to-use t:slim X2 insulin pump with Basal-IQ
technology uses glucose values from an integrated Dexcom G6
continuous glucose monitor to predict and help prevent lows with
zero fingersticks*. It is up to 38 percent smaller than other
insulin pumps, holds up to 300 units of insulin, and is capable of
remote software updates using a personal computer, offering the
potential for in-warranty users to access new features as they meet
necessary regulatory requirements.
Tandem Diabetes Care, Basal-IQ and t:slim X2 are trademarks of
Tandem Diabetes Care, Inc., registered in the U.S. and other
countries.
Footnotes
*If your glucose alerts and readings from the G6 do not match
symptoms or expectations, use a blood glucose meter to make
diabetes treatment decisions.
1Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al.
Predictive low-glucose suspend reduces hypoglycemia in adults,
adolescents, and children with type 1 diabetes in an at-home
randomized crossover study: Results of the PROLOG trial.
Diabetes Care. 2019;41(10):2155-2161.
doi:10.2337/dc18-0771.
2For a list of compatible smart devices, please visit
www.dexcom.com/compatability. Internet connectivity required for
data sharing. Following requires the use of the Follow App. The
Dexcom Follow App is not included as part of the Dexcom G6 Mobile
CGM System. Followers must download the Dexcom Follow App
separately. Internet connectivity required to access Dexcom Follow.
Followers should always confirm readings on the Dexcom
G6 Mobile App or Receiver before making treatment
decisions.
3For a list of compatible smart devices, visit
dexcom.com/compatibility.
4Calhoun P, Johnson TK, Hughes J, Price D, Balo AK.
Resistance to Acetaminophen Interference in a Novel Continuous
Glucose Monitoring System. J Diabetes Sci Technol.
2018:1932296818755797.